Novo Nordisk is working on a new obesity drug that could help ... Shares of the company have taken a hit in the past few ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

A new study shows that Ozempic may help ease arthritis knee pain in people with obesity. Here's what to know about the study and whether semaglutide can truly help reduce knee pain, according to ...

Sahpra warns of falsified diabetes treatments Ozempic and Mounjaro sold online for weight loss, posing health risks.

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...

In the U.S. Veterans Affairs Medical System, Black patients and those of Asian or Native American ancestry were less likely to receive semaglutide than white patients for diabetes or weight loss, ...

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...